Erez Israeli, CEO of Dr Reddy's Laboratories highlights the moves he is undertaking to position his company as a market ...

Dr. Reddy's Laboratories Ltd. 500124 shares advanced 2.39% to 1,303.00 Indian rupees Wednesday, on what proved to be an ...

RDY misses on earnings but beats on revenues in the fiscal second quarter. The bottom line suffers due to a one-time ...

Dr. Reddy's Laboratories Ltd. 500124 shares inched up 0.36% to 1,272.55 Indian rupees Tuesday, on what proved to be an ...

In a report released today, Balaji Prasad from Barclays maintained a Buy rating on Dr Reddy’s Laboratories (RDY – Research Report), ...

The drugmaker’s total revenue from operations in the second quarter of current fiscal rose 16.5 per cent to ₹8,016 crore.

Dr Reddy's expects overall sales to grow in double digits, with branded business in India and emerging markets growing in ...

Dr. Reddy’s Laboratories Ltd ( (RDY) ) has released its Q2 earnings. Here is a breakdown of the information Dr. Reddy’s ...

Out of the 40 analysts that track Dr. Reddy's, 13 of them have a 'Buy' recommendation, while 16 of them have a 'Sell' call.

Dr. Reddy’s (DRRD) Q2FY25 EBITDA was largely in line with our estimate. The base business margins and US sales ex of ...

Systematix upgraded the stock rating to 'hold' and hiked target price to Rs 1,414 apiece, while Dolat Capital upgraded rating ...

Pharma major Dr Reddy’s Laboratories’ net profit declined 9 per cent at ₹1,341 crore in the second quarter ended September 30 ...